In a mouse model of hyperlipidaemia, the combination of the PCSK9 inhibitor alirocumab, a monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein) evinacumab, and atorvastatin not only reduced LDL cholesterol by 73% but also regressed atherosclerosis.
Read the article: Pouwer MG, et al. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res 2019; doi: 10.1194/jlr.RA119000419. [Epub ahead of print] PUBMED https://www.ncbi.nlm.nih.gov/pubmed/31843957
Read the accompanying editorial: Hurt-Camejo E. Combination ANGPTL3, PCSK9 and statin therapy drives remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model. J Lipid Res 2020;doi: 10.1194/jlr.C120000650. [Epub ahead of print]
PUBMED https://www.ncbi.nlm.nih.gov/pubmed/31980481
Related content
Evinacumab, ANGPTL3 inhibitor, awarded breakthrough status by FDA
EAS Congress Innsbruck: Mixed results with novel agents in homozygous FH
